touchNEUROLOGY had the pleasure of meeting with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) and Ralf Reilmann (Founding Director, George Huntington Institute, Münster, Germany), to discuss the clinical utility of pridopidine in Huntington’s disease, and the ongoing PROOF-HD study.
The abstract entitled ‘The PROOF-HD Study: Pridopidine’s Outcome on Function in Huntington Disease’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
Questions:
- Could you tell us a little about pridopidine and its mechanism of action? (1:00)
- What have clinical studies to date taught us about the clinical utility of pridopidine in Huntington’s disease, and what have been the limitations of these studies? (3:43)
- How have previous data been used to optimise the design of the PROOF-HD trial? (12:41)
Disclosures: Andrew Feigin has served as a consultant for NeuExcell, Prilenia, Stealth, and Voyager. Ralf Reilmann has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
